Sanofi SA vs SoundHound AI Inc — how do they compare? Sanofi SA trades at $40.07 (market cap $95.18B), while SoundHound AI Inc trades at $5.39 (market cap $2.45B). The key difference: Sanofi SA is far larger — about 38.8× SoundHound AI Inc's market cap, and Sanofi SA pays a 6.01% dividend while SoundHound AI Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and SoundHound AI Inc for 23 Days on average.
| SNY | SOUN | |
|---|---|---|
Market Cap | $95.18B | $2.45B |
Volume | 2,995,646 | 16,881,989 |
Sector | Health | Technology |
52-Week High | $52.34 | $21.40 |
52-Week Low | $39.51 | $5.52 |
Typical Hold Time | 94 Days | 23 Days |
Enterprise Value | $114.48B | $2.25B |
Dividend Yield | 6.01% | — |
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
SoundHound AI (SOUN) trades at $5.52, down 1.95% amid bearish technical signals despite recent earnings beats. The company shows strong revenue growth with 2025 revenue of $168.92M and projected 2026 revenue of $203M, but faces significant profitability challenges with a -67.45% net income margin. Recent developments include expansion into banking AI agents and the OASYS Edge embedded architecture launch for vehicles and smart devices.
While analyst consensus remains bullish with a $9.33 price target (75% buy ratings), the stock faces headwinds from persistent losses, negative cash flow projections for 2026, and insider selling activity. The key investment thesis hinges on voice AI adoption growth versus the company's ability to achieve profitability amid high valuation multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →